ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
Amir Mehrvarz SarshekehJumanah AlshenaifiJason RoszikGaniraju C ManyamShailesh M AdvaniRiham KatkhudaAnuj VermaMichael LamJason WillisJohn Paul ShenJeffrey MorrisJennifer S DavisJonathan M LoreeHey Min LeeJaffer A AjaniDipen Maheshbhai MaruMichael James OvermanScott KopetzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The immunogenicity of ARID1A-mutant cases is likely due to an increased level of neoantigens resulting from increased tumor mutational burden and frameshift mutations. Tumors with ARID1A mutation may be more susceptible to immune therapy-based treatment strategies and should be recognized as a unique molecular subgroup in future immune therapy trials.